Latest News
2023.7.12
Results from preclinical study will be presented by Dr. Juanjuan Ye at the 82nd Annual Meeting of the Japanese Cancer Association (Yokohama, September 21-23, 2023).
Title：Targeting carbohydrate sulfotransferase 15 diminishes both tumoral and lymph node MDSCs in pancreatic tumor in mice
Presentation No.：E-3051
Presentation Type：English Oral Sessions
Date and Time：Sep. 23 (Sat.) 13:30-14:45
The 82nd Annual Meeting of the Japanese Cancer Association
https://www.c-linkage.co.jp/jca2023/en/index.html
2023.7.3
Results from preclinical study were presented by Dr. Juanjuan Ye at the 2nd JCA-AACR* Precision Cancer Medicine International Conference (Kyoto, June 28-30, 2023).
*JCA-AACR : Japanese Cancer Association (JCA)/American Association for Cancer Research (AACR)
Title: Silencing of Tumoral Carbohydrate Sulfotransferase 15 Reactivates Lymph Node T cells in Pancreatic Cancer in Mice
Presentation Type: Poster
2023.6.2
Results from preclinical study were presented by Dr. Juanjuan Ye at American Society of Clinical Oncology (ASCO) annual meeting 2023.
Title: Effect of locoregional injection of RNA oligonucleotide targeting carbohydrate sulfotransferase 15 on both tumoral and lymph node MDSCs and T cell infiltration in pancreatic tumor in mice.
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e16310?af=R
2023.5.30
Results from preclinical study were published by Dr. Juanjuan Ye in European Journal of Immunology.
Title: Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice.
https://onlinelibrary.wiley.com/journal/15214141
https://pubmed.ncbi.nlm.nih.gov/37248998/
2022.11.18
The results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were published in the LANCET eClinicalMedicine.
Fujisawa T et al. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial. The LANCET eClinicalMedicine 2023;55: 101731
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00461-8/fulltext